申请人:Rhone-Poulenc Rorer Pharmaceuticals Inc.
公开号:US06057369A1
公开(公告)日:2000-05-02
This invention is directed to compounds of formula I: ##STR1## wherein the variables are as described herein. Compounds within the scope of the present invention possess useful properties, more particularly pharmaceutical properties. They are especially useful for inhibiting the production or physiological effects of TNF in the treatment of a patient suffering from a disease state associated with a physiologically detrimental excess of tumor necrosis factor (TNF). Compounds within the scope of the present invention also inhibit cyclic AMP phosphodiesterase, and are useful in treating a disease state associated with pathological conditions that are modulated by inhibiting cyclic AMP phosphodiesterase, such disease states including inflammatory and autoimmune diseases, in particular type IV cyclic AMP phosphodiesterase. Compounds within the scope of the present invention may also inhibit an MMP, and are useful in treating a disease state associated with pathological conditions that are modulated by inhibiting MMPs, such disease states involve tissue breakdown and those associated with a physiologically detrimental excess of TNF. The present invention is therefore also directed to the pharmaceutical use of the compounds, pharmaceutical compositions containing the compounds, intermediates leading thereto and methods for the preparation of the compounds and their intermediates.
本发明涉及式I的化合物:##STR1## 其中变量如本文所述。本发明所涵盖的化合物具有有用的性质,特别是药物性质。它们在治疗患有与生理有害的肿瘤坏死因子(TNF)过度相关的疾病状态的患者中抑制TNF的产生或生理效应特别有用。本发明所涵盖的化合物还抑制环磷酸腺苷磷酸二酯酶,并且在治疗与抑制环磷酸腺苷磷酸二酯酶有关的病理条件的疾病状态中有用,这些疾病状态包括炎症和自身免疫性疾病,特别是第四型环磷酸腺苷磷酸二酯酶。本发明所涵盖的化合物还可能抑制MMP,并且在治疗与抑制MMP有关的病理条件的疾病状态中有用,这些疾病状态涉及组织分解和与TNF过度有害相关的疾病状态。因此,本发明还涉及化合物的药物用途、含有该化合物的药物组合物、导致其中间体的中间体以及制备该化合物及其中间体的方法。